胃肠道功能障碍的概况在前期到晚期的帕金森病中
Marta Camacho1, Julia C Greenland2,3, Cyrus Daruwalla2,3
1Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. msc72@cam.ac.uk.
NPJ Parkinson's disease
|May 10, 2025
概括
胃肠道功能障碍在帕金森病 (PD) 和孤立的REM睡眠行为障碍 (iRBD) 中很常见,但肠道症状不会随着疾病的进展而恶化. 肠道功能障碍可能是帕金森氏症表型的关键因素.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
- 睡眠医学 睡眠医学
背景情况:
- 胃肠道功能障碍 (GID) 在帕金森病 (PD) 中越来越多地被认可.
- 目前尚不清楚GID和PD进展之间的关系.
- 孤立的REM睡眠行为障碍 (iRBD) 与PD具有共同的潜在病理.
研究的目的:
- 调查PD和iRBD中GID的患病率和特征.
- 为了确定GID是否与疾病严重程度或PD进展相关.
- 在PD患者中评估GID随时间的稳定性.
主要方法:
- 招募了404名PD病例,37名iRBD患者和105名对照.
- 管理了PD的胃肠道功能障碍量表 (GIDS-PD) 和疾病严重程度评估.
- 在一组PD患者中使用"蓝色大便挑战"测量全肠传输时间 (WGTT).
主要成果:
- 与对照组相比,iRBD和PD的胃肠道症状更为普遍.
- 患PD患者的WGTT显著高于对照组.
- 调整后,疾病阶段没有预测GIDS-PD便秘或肠道易怒度得分.
- 在4年的纵向评估中,GIDS-PD得分和WGTT保持稳定.
结论:
- 肠道功能障碍是帕金森病患者的一个子集的常见特征.
- 随着时间的推移,GID似乎稳定,可能与疾病阶段没有直接关联.
- 肠道功能障碍可以作为帕金森病患者分层和管理的表型标记.
相关概念视频
Parkinson's Disease: Treatment
161
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
161
Parkinson's Disease: Overview
342
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
342
Gastrointestinal Motility Disorders
220
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
220
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
210
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
210
Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K


